These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25998299)

  • 1. Erratum. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes care 2015;38:394-402.
    Lewin A; DeFronzo RA; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
    Diabetes Care; 2015 Jun; 38(6):1173. PubMed ID: 25998299
    [No Abstract]   [Full Text] [Related]  

  • 2. Erratum. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes care 2015;38:384-393.
    DeFronzo RA; Lewin A; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
    Diabetes Care; 2015 Jun; 38(6):1173. PubMed ID: 25998298
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
    Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
    Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension.
    Gomis R; Owens DR; Taskinen MR; Del Prato S; Patel S; Pivovarova A; Schlosser A; Woerle HJ
    Int J Clin Pract; 2012 Aug; 66(8):731-740. PubMed ID: 22691164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
    Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.
    Macha S; Koenen R; Sennewald R; Schöne K; Hummel N; Riedmaier S; Woerle HJ; Salsali A; Broedl UC
    Clin Ther; 2014 Feb; 36(2):280-90.e1. PubMed ID: 24491572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.
    Neumiller JJ
    Ann Pharmacother; 2012 Mar; 46(3):358-67. PubMed ID: 22318932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia.
    Haak T
    Adv Ther; 2012 Dec; 29(12):1005-15. PubMed ID: 23212658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
    Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ
    Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.
    Lajara R
    Expert Opin Pharmacother; 2012 Dec; 13(18):2663-71. PubMed ID: 23137412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.
    Macha S; Rose P; Mattheus M; Cinca R; Pinnetti S; Broedl UC; Woerle HJ
    Diabetes Obes Metab; 2014 Feb; 16(2):118-23. PubMed ID: 23859534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
    Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Toth PP
    Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.
    Koliaki C; Doupis J
    Adv Ther; 2012 Dec; 29(12):993-1004. PubMed ID: 23184570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
    Graefe-Mody U; Friedrich C; Port A; Ring A; Retlich S; Heise T; Halabi A; Woerle HJ
    Diabetes Obes Metab; 2011 Oct; 13(10):939-46. PubMed ID: 21672124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Jentadueto® (linagliptin plus metformin).
    Scheen AJ
    Expert Opin Drug Saf; 2013 Mar; 12(2):275-89. PubMed ID: 23421949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
    Zeng Z; Yang JK; Tong N; Yan S; Zhang X; Gong Y; Woerle HJ
    Curr Med Res Opin; 2013 Aug; 29(8):921-9. PubMed ID: 23672632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes.
    Raedler LA
    Am Health Drug Benefits; 2015 Mar; 8(Spec Feature):171-5. PubMed ID: 26629285
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.